- Home
- DCH vs MNKD Comparison
DCH vs MNKD Comparison
Compare DCH & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DCH | MNKD |
|---|---|---|
| Founded | 1994 | 1991 |
| Country | United States | United States |
| Employees | 20000 | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 1998 | 2004 |
Fundamental Metrics
Financial Performance| Metric | DCH | MNKD |
|---|---|---|
| Price | $6.64 | $3.70 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $10.50 | $8.69 |
| AVG Volume (30 Days) | 3.2M | ★ 4.8M |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,836,700,000.00 | $348,966,000.00 |
| Revenue This Year | $82.65 | $35.81 |
| Revenue Next Year | $4.20 | $11.89 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 22.23 |
| 52 Week Low | $4.92 | $2.23 |
| 52 Week High | $8.75 | $6.51 |
Technical Indicators
Market Signals| Indicator | DCH | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 63.53 | 43.61 |
| Support Level | $5.12 | $3.30 |
| Resistance Level | $6.93 | $3.94 |
| Average True Range (ATR) | 0.33 | 0.21 |
| MACD | 0.13 | -0.03 |
| Stochastic Oscillator | 74.46 | 1.80 |
Price Performance
Historical ComparisonAbout DCH Dauch Corporation Common Stock
Dauch Corp is a world-wide Tier 1 Automotive Supplier, Dauch designs, engineers and manufactures Driveline and Metal Forming technologies to support electric, hybrid and internal combustion vehicles.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.